Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Afamitresgene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Afamitresgene autoleucel overview
ADPA-2M4 is under development for the treatment of solid tumors including synovial sarcoma, myxoid/round cell liposarcoma, esophageal cancer (squamous and adenocarcinoma), esophagogastric junction cancer, melanoma, urothelial, bladder, ovarian, squamous non-small cell lung, peripheral nerve sheath tumor (neurofibrosarcoma), neuroblastoma, osteosarcoma and gastric cancer. The therapeutic candidate constitutes autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) targeting MAGEA4. It is administered through parenteral and intravenous route.
It was under development for the treatment of recurrent head and neck squamous cell carcinoma.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics (Adaptimmune), formerly Adaptimmune Therapeutics is a clinical stage bio pharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform that engineers the T-cells to identify and exterminate cancer, including solid tumors. The company’s pipeline products include NY-ESO TCR for synovial sarcoma and multiple myeloma; MAGE A4 TCR for multiple solid tumors; AFP TCR for hepatocellular cancer; and MAGE-A10 TCR for bladder, melanoma, and head and neck cancer. The company has presence in the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of Afamitresgene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.